Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eque-cel in newly diagnosed Mayo Stage IIIb AL amyloidosis
NCT07055724Phase 2Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of equecabtagene autoleucel in amyloid light chain amyloidosis, sponsored by Reindeer Biotech. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07055724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055724.